References
- Priority eye diseases. Accessed March 27, 2014 from: http://www.who.int/blindness/causes/priority/en/index9.html
- Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005;123:321–327
- Agarwal R, Gupta SK, Agarwal P, et al. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol 2009;57:257–266
- Stuart A. Genetic testing for inherited eye disease: why, how, and who. Accessed March 27, 2014 from: http://www.aao.org/publications/eyenet/201206/comprehensive.cfm
- Rahi JS. Childhood blindness: a UK epidemiological perspective. Eye 2007;21:1249–1253
- Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006;6:58
- MacDonald IM, Tran M, Musarella MA. Ocular genetics: current understanding. Surv Ophthalmol 2004;49:159–196
- Burke W, Tarini B, Press N, et al. Genetic screening. Epidemiol Rev 2011;33:148–164
- Mezer E, Babul-Hirji R, Wise R, et al. Attitudes regarding predictive testing for retinitis pigmentosa. Ophthalmic Genet 2007;28:9–15
- Billings PR, Kohn MA, de Cuevas M, et al. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992;50:476–482
- Sutherland JE, Day MA. Genetic counseling and genetic testing in ophthalmology. Curr Opin Ophthalmol 2009;20:343–350
- Liu MM, Tuo J, Chan CC. Republished review: gene therapy for ocular diseases. Postgrad Med J 2011;87:487–495
- Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643–650
- Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Hum Gene Ther 2011;22:523–529
- Goldmann T, Overlack N, Möller F, et al. A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Mol Med 2012;4:1186–1199
- MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014;383:1129–1137
- Moore T, Burton H. Genetic ophthalmology in focus: report of a UKGTN Working Party. Foundation for Genomics and Population Health. 2008
- Smith LE. Bone marrow-derived stem cells preserve cone vision in retinitis pigmentosa. J Clin Invest 2004;114:755–757
- Henneman L, Timmermans DR, Van Der Wal G. Public attitudes toward genetic testing: perceived benefits and objections. Genet Test 2006;10:139–145
- Bernhardt JM, Lariscy RA, Parrott RL, et al. Perceived barriers to internet-based health communication on human genetics. J Health Commun 2002;7:325–340
- Singer E, Antonucci T, Van Hoewyk J. Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet Test 2004;8:31–43
- Christensen KD, Jayaratne TE, Roberts JS, et al. Understandings of basic genetics in the United States: results from a national survey of black and white men and women. Public Health Genomics 2010;13:467–476
- Willis TA, Potrata B, Ahmed M, et al. Understanding of and attitudes to genetic testing for inherited retinal disease: a patient perspective. Br J Ophthalmol 2013;97:1148–1154
- Bong C, Potrata B, Hewison J, et al. Attitudes of patients and relatives/carers towards genetic testing for inherited retinal disease. Eye 2010; 24:1621–1622
- Healey DL, Craig JE, Wilkinson CH, et al. Attitudes to predictive DNA testing for myocilin glaucoma: experience with a large Australian family. J Glaucoma 2004;13:304–311
- Al-Saikhan FI. The gene therapy revolution in ophthalmology. Saudi J Ophthalmol 2013;27:107–111
- Gottweis H. Gene therapy and the public: a matter of trust. Gene Ther 2002;9:667–669
- Royal National Institute of Blind People. Accessed September 4, 2014 from: http://www.rnib.org.uk